(CercleFinance.com) – Cellectis lost almost 5% on the Paris Stock Exchange on Monday following a placement of shares and stock warrants by Calyxt, its American synthetic biology subsidiary based on plants.
The placement, made with an institutional investor, involves 3.88 million Calyxt common shares at a unit price of 1.41 dollars, for a total of 5.47 million dollars.
The transaction also provides for the issue of 3.88 million pre-financed stock warrants at $1.41 per warrant, ie an additional subscription of $5.47 million.
This last component will allow the Calyxt investor, whose name has not been disclosed, to acquire the same number of additional common shares of at a price of $0.0001 per share,
In addition, 7.76 million warrants will enable it to subscribe to a maximum of 7.76 million additional ordinary shares, still on the basis of the same price, representing an additional amount of 10.9 million dollars in the event full exercise.
The transaction will have a particularly dilutive effect since Cellectis’ stake in Calyxt will be reduced from 61.7% to 56.1% of the capital following the first operation.
Cellectis’ stake could even fall to 51.4% if all of the 3.88 million pre-funded stock warrants are exercised, or even to 44.1% if all of the shares are exercised. of the 7.76 million vouchers.
As of December 31, Calyxt’s cash and cash equivalents amounted to $13.7 million, while finance lease obligations amounted to $17.9 million.
In its press release, Cellectis specifies that the continuation of Calyxt’s activities remains conditional on its ability to raise new financing.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
